Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 5/20 | 0.70 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.54 |
| ▸ | NAMPT | P43490 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.52 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL323824 | 1.00 | FFAR1 (0.70) | FFAR1HDAC4ALDH1A1SLC9A1HPGD | |
| SCHEMBL5315326 | 1.00 | FFAR1 (0.70) | FFAR1HDAC4ALDH1A1SLC9A1HPGD | |
| SCHEMBL1172743 | 1.00 | FFAR1 (0.70) | FFAR1HDAC4ALDH1A1SLC9A1HPGD | |
| SCHEMBL2034678 | 1.00 | FFAR1 (0.70) | FFAR1HDAC4ALDH1A1SLC9A1HPGD | |
| SCHEMBL8295172 | 1.00 | FFAR1 (0.70) | FFAR1HDAC4ALDH1A1SLC9A1HPGD | |
| SCHEMBL5217474 | 1.00 | FFAR1 (0.70) | FFAR1HDAC4ALDH1A1SLC9A1HPGD | |
| SCHEMBL323823 | 1.00 | FFAR1 (0.70) | FFAR1HDAC4ALDH1A1SLC9A1HPGD | |
| SCHEMBL4126470 | 1.00 | FFAR1 (0.70) | FFAR1HDAC4ALDH1A1SLC9A1HPGD | |
| Hydrochloric Acid SCHEMBL5089207 | 0.98 | FFAR1 (0.68) | FFAR1HDAC4ALDH1A1SLC9A1HPGD | |
| Hydrochloric Acid SCHEMBL5089203 | 0.98 | FFAR1 (0.68) | FFAR1HDAC4ALDH1A1SLC9A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118290491-A | Copper nanocluster and preparation method thereof | 清华大学 | 2024-07-05 | — | — | CN | claimed |
| EP-2231611-A1 | NOVEL 2-PYRROLIDINYL-3-AMIDO-6-AMINO-PYRIDINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL ACTIVATORS | NeuroSearch A/S (DK) | 2010-09-29 | — | — | EP | claimed |
| WO-2009074593-A1 | NOVEL 2-PYRROLIDINYL-3-AMIDO-6-AMINO-PYRIDINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL ACTIVATORS | NEUROSEARCH A/S (DK) | 2009-06-18 | — | — | WO | claimed |
| US-20240239739-A1 | COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | AURIMMED PHARMA, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240239739-A1 | COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | AURIMMED PHARMA, INC. | 2024-07-18 | — | — | US | disclosed |
| CN-118290491-A | Copper nanocluster and preparation method thereof | 清华大学 | 2024-07-05 | — | — | CN | disclosed |
| US-20210130285-A1 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | AURIMMED PHARMA, INC. | 2021-05-06 | — | — | US | disclosed |
| US-10793515-B2 | Compounds advantageous in the treatment of central nervous system diseases and disorders | AURIMMED PHARMA, INC. (US) | 2020-10-06 | — | — | US | disclosed |
| WO-2017066103-A1 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | AURIMMED PHARMA, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| US-20160137592-A1 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | AURIMMED PHARMA, INC. | 2016-05-19 | — | — | US | disclosed |
| US-20160137592-A1 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | AURIMMED PHARMA, INC. | 2016-05-19 | — | — | US | disclosed |
| US-20070135415-A1 | TRICYCLIC COMPOUNDS PROTEIN KINASE INHIBITORS FOR ENHANCING THE EFFICACY OF ANTI-NEOPLASTIC AGENTS AND RADIATION THERAPY | AGOURON PHARMACEUTICALS, INC. | 2007-06-14 | — | — | US | disclosed |
| US-20070135415-A1 | TRICYCLIC COMPOUNDS PROTEIN KINASE INHIBITORS FOR ENHANCING THE EFFICACY OF ANTI-NEOPLASTIC AGENTS AND RADIATION THERAPY | AGOURON PHARMACEUTICALS, INC. | 2007-06-14 | — | — | US | disclosed |
| EP-1689729-A1 | TETRONIC AND TETRAMIC ACIDS AS INHIBITORS OF BETA-SECREASE | F. Hoffmann-La Roche AG (CH) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005058857-A1 | TETRONIC AND TETRAMIC ACIDS AS INHIBITORS OF BETA-SECREASE | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-30 | — | — | WO | disclosed |
| US-20050119329-A1 | Tetronic and tetramic acids | HOFFMANN-LA ROCHE INC. | 2005-06-02 | — | — | US | disclosed |
| US-6620849-B2 | Bicyclic sulfanimde compounds useful for the treatment of cardiac arrhythmias | ICAFEN, INC. | 2003-09-16 | — | — | US | disclosed |
| US-20020169161-A1 | Potassium channel inhibitors | ICAGEN, INC. | 2002-11-14 | — | — | US | disclosed |
| US-6172091-B1 | METABOLIC CALCIUM IMBALANCE AND OSTEOPOROSIS | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2001-01-09 | — | — | US | disclosed |
| WO-2000021910-A2 | 1,2-DISUBSTITUTED CYCLOPROPANES | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2000-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130285-A1 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | SMN1; SMN2, HDAC6, HDAC3 | FFAR1 553/4885HDAC4 18/4885ALDH1A1 1158/4885 |
| US-20050119329-A1 | Tetronic and tetramic acids | BACE1, PSEN1, BACE2 | FFAR1 601/4885HDAC4 629/4885ALDH1A1 2826/4885 |
| US-20160137592-A1 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | SMN1; SMN2, HDAC6, HDAC3 | FFAR1 553/4885HDAC4 18/4885ALDH1A1 1158/4885 |
| US-10793515-B2 | Compounds advantageous in the treatment of central nervous system diseases and disorders | SMN1; SMN2, HDAC6, CTSA | FFAR1 543/4885HDAC4 41/4885ALDH1A1 1386/4885 |
| US-20070135415-A1 | TRICYCLIC COMPOUNDS PROTEIN KINASE INHIBITORS FOR ENHANCING THE EFFICACY OF ANTI-NEOPLASTIC AGENTS AND RADIATION THERAPY | CHEK1, CHEK2, CHKA | FFAR1 3275/4885HDAC4 970/4885ALDH1A1 4198/4885 |
| US-20240239739-A1 | COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | SMN1; SMN2, HDAC6, CTSA | FFAR1 543/4885HDAC4 41/4885ALDH1A1 1386/4885 |
| US-20020169161-A1 | Potassium channel inhibitors | KCNN2, KCNH2, KCNJ2 | FFAR1 3392/4885HDAC4 1131/4885ALDH1A1 4168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.